DOCSLIB.ORG

Linear Correlation Between Phenobarbital Dose and Concentration in Alcohol Withdrawal Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Linear Correlation Between Phenobarbital Dose and Concentration in Alcohol Withdrawal Patients Dan Med Bul ϧϩ/Ϫ August ϤϢϣϢ DANISH MEDICAL BULLETIN ϣ Linear correlation between phenobarbital dose and concentration in alcohol withdrawal patients Karen Tangmose1, Mogens Kai Nielsen1, Peter Allerup2 & Jakob Ulrichsen1 ABSTRACT definite conclusions about the relative effectiveness and ORIGINAL ARTICLE INTRODUCTION: Barbiturates are potent drugs for treat- safety of benzodiazepines against other alcohol with- 1) Psychiatric Centre ment of alcohol withdrawal symptoms, but they entail a risk drawal drugs [5]. Although barbiturates have never been Gentofte, Copenhagen of over-dosage and respiratory depression. The purpose of tested against placebo in randomized trials, barbital was University Hospital, the present study was to investigate the correlation shown to be more efficient than diazepam in the Denmark between phenobarbital dose and phenobarbital blood treatment of delirium tremens [6]. A major concern in 2) The Danish concentration in patients withdrawing from long-term University of relation to the use of barbiturates, including phenobar- Education, Copen- alcohol intoxication. bital, is that these drugs supposedly carry a risk of fatal hagen, Denmark MATERIAL AND METHODS: A total of 497 patients who were intoxication by causing respiratory depression. In hospitalized for treatment of alcohol withdrawal symptoms another retrospective study conducted at our depart- Dan Med Bul during an 18-month period were enrolled in the study. ment, we only detected two cases with respiratory 2010;57(8):A4141 Phenobarbital 200 mg was administered orally every 30 or depression among 73 patients with delirium tremens 60 minutes in response to the observed symptoms. Within who had been treated with phenobarbital during an the first 24 hours after admission, i.e. at 8 AM, blood was 8-year period. No respiratory problems were registered collected for determination of phenobarbital concentration, among 22 patients with pre-delirium in the same study, and the cumulated dose of phenobarbital at the time of the i.e. patients who had physical withdrawal symptoms and blood sampling was registered. RESULTS: The mean cumulated phenobarbital dose at the visual hallucinations, but showed no clouding of con- time of the blood sampling was 877 mg ± 557 mg, while the sciousness [7]. mean plasma phenobarbital concentration was 104 It is a widespread hypothesis among Danish phys- micromol/l ± 62 micromol/l. A statistically significant linear icians and nurses treating alcohol withdrawal patients correlation between phenobarbital dose and concentration that the absorption rate of phenobarbital may decrease was found for both males and females as 83% and 84% of due to slow gastric emptying, leading to a potential risk the variation in drug concentration, respectively, could of over-dosage if large amounts of phenobarbital remain be explained by the phenobarbital dose. We observed in the gastrointestinal system when sedation caused by no serious complications of the phenobarbital treatment the phenobarbital already absorbed sets in. This hypo th- – including respiratory problems or severe sedation. esis is not based on scientific evidence. In fact, the ab- DISCUSSION: The strong linear correlation between sorption rate in non-alcoholic subjects is quite rapid [8] phenobarbital dose and concentration suggests that and there is no reason to assume that alcoholics should absorption of plasma phenobarbital from the gastrointe s- differ in this regard. The purpose of the current study tinal system is highly predictable. was to investigate the hypothesis of delayed phenobar- bital absorption by analysing blood samples from pa- tients who were being treated for alcohol withdrawal, Alcohol withdrawal symptoms include tremor, agitation, and by studying the correlation between phenobarbital tachycardia and sweating [1]. Some patients develop dose and its concentration. more severe symptoms such as seizures, visual hallu- cinations or delirium tremens. The latter condition is a MATERIAL AND METHODS true medical emergency which, if left untreated, has a This prospective study comprised patients of either sex mortality rate of 15% [2]. In Denmark, barbiturates have who were admitted to Psychiatric Centre Gentofte, been used for a century in the treatment of alcohol Copenhagen University Hospitals, Denmark, for detoxi- withdrawal symptoms including delirium tremens [3]. fication or treatment for alcohol withdrawal symptoms Worldwide, benzodiazepines are regarded as the drug of in the period from 20 February 2007 to 24 August 2008. choice in alcohol withdrawal [4]. In a recent Cochrane For each patient we registered gender, age and blood review, benzodiazepines were found to be more effi - alcohol concentration upon admittance. Blood samples cient than placebo, whereas it was not possible to draw for measurement of phenobarbital plasma concentra- Ϥ DANISH MEDICAL BULLETIN Dan Med Bul ϧϩ/Ϫ August ϤϢϣϢ tion were collected at 08.00 AM, and the cumulated certified psychiatry specialist who decided whether the phenobarbital doses were registered at the time the patient had Wernicke’s encephalopathy. This syndrome blood samples were taken and upon discharge. The was defined clinically by the presence of any of the phenobarbital concentration in blood was measured by three mentioned symptoms, provided that these could the hospital’s Department of Clinical Chemistry as part not be accounted for by alcohol intoxication or delirium. of their daily routine using Vitros MicroSlide technology Statistical analyses of the relation between pheno- in a fully automated process (Ortho Clinical Diagnostics, barbital concentration (micromol/l) and phenobarbital UK). Since phenobarbital metabolizes slowly with a half- dose (mg) was performed as simple linear regression life of approximately 90 hours [8], patients who had analyses and generalized linear modelling. The latter received phenobarbital 14 days before admission were method was used to compare marginal changes in excluded. Thus, the study did not include those who had plasma phenobarbital (p-phenobarbital) concentration been treated for alcohol withdrawal at the ward within due to differences in the phenobarbital dose between the preceding two weeks of admission. Using the with- males and females. The level of significance was p = 0.05 drawal items tremor, sweating, tachycardia (pulse rate > and all tests were double-sided. Quantitative data are 90), increased psychomotor activity and the patients’ presented as mean ± standard deviation. subjective experience of restlessness, a nurse made a global rating as to whether withdrawal symptoms were RESULTS present or not [9]. In addition, vital signs such as pulse A total of 497 cases, 305 men and 192 women, were rate, blood pressure and temperature were measured admitted for alcohol detoxification or treatment for regularly in patients who were awake. In the sleeping alcohol withdrawal symptoms. The study population patients, a nurse observed if respiration was regular consisted of 241 patients among whom 141 patients without signs of airway obstruction and also recorded were only admitted once while 95 patients were admit- the rate of respiration on an hourly basis. In patients ted twice or more. Two of the 241 patients each de - who were awake, 200 mg phenobarbital was adminis- veloped DT once and were included in the present study tered orally every hour if withdrawal symptoms were as they were not transferred to the closed ward. In present according to the rating of the nurse, i.e. addition, a total of 23 cases (19 patients) who were administration was undertaken if symptoms were either delirious upon admittance or developed DT present. In case of severe symptoms, the same dose of during the withdrawal phase were admitted to a closed phenobarbital was administered every 30 minutes. The ward and not included in the study. The mean age of the need for further phenobarbital was evaluated by the study population was 51.9 ± 9.5 years, the mean physician in charge when 1,200 mg of phenobarbital had duration of hospitalization was 1.34 ± 0.59 day and the been administered and subsequently after administra- mean alcohol concentration at admission was 1.5 ± 1 g/l. tion of each cumulated 600 mg dose, but there was no Some patients did not receive phenobarbital as they did limit to the total cumulated dose of phenobarbital. The not develop withdrawal signs, in some cases blood treatment aimed to terminate the physical withdrawal samples were not collected in the morning on day 2, and symptoms and sleep from which the patient could be some patients were excluded because they had received woken by light or moderate touch. phenobarbital within the previous two weeks. Thus Whereas the present study population was treated correlation be tween phenobarbital dose and concentra- at the Emergency Ward of the Psychiatric Department, tion was performed on a total of 348 patients (212 men the majority of patients who were admitted with deli r- and 136 women). The mean cumulated phenobarbital ium tremens or who developed delirium tremens (DT) dose at the time of blood sampling was 877 mg ± 557 during therapy were transferred to and treated at a and the mean total cumulated phenobarbital dose was closed ward. As blood phenobarbital levels were not sys- 1,005 mg ± 659 mg. The mean p-phenobarbital concen- tematically measured in patients admitted to the closed tration was 104 ± 62 micromol/l. wards, these subjects were not included in the study. Wernicke’s encephalopathy was observed in 49 of The patients
Load more

Recommended publications
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • Comparative Enhancing Effects of Phenobarbital, Amobarbital
    [CANCER RESEARCH 35,2884 2890, October 1975] Comparative Enhancing Effects of Phenobarbital, Amobarbital, Diphenylhydantoin, and Dichlorodiphenyltrichloroethane on 2-Acetylaminofluorene-induced Hepatic Tumorigenesis in the Rat Carl Peraino, R. J. Michael Fry, Everett Staffeldt, and John P. Christopher 2 Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois 60439 SUMMARY INTRODUCTION Earlier studies showed that phenobarbital feeding en- In earlier studies (27, 29), the prolonged feeding of hanced hepatic tumorigenesis in rats previously fed 2- phenobarbital to rats that had previously been fed AAF 3 for acetylaminofluorene for a brief period. As part of an a brief period markedly increased the subsequent incidence investigation of the mechanism of this enhancement, the of liver tumors. Using this sequential feeding regime, the present study evaluated the relative enhancing abilities of present study evaluated the relative tumorigenic enhancing amobarbital, diphenylhydantoin, and dichlorodiphenyltri- abilities of other compounds that, to varying degrees, chloroethane (DDT), agents that resemble phenobarbital to resemble phenobarbital in their effects on liver structure and varying degrees in their effects on liver structure and metabolism. The substances examined were amobarbital, metabolism. A comparison of hepatic tumor yields in rats diphenylhydantoin, and DDT. Table 1 compares relevant fed 2-acetylaminofluorene, followed by the test substance characteristics of these agents with those of phenobarbital, (sequential treatment), showed that amobarbital and di- reviewed previously (27, 29). Amobarbital is closest to phenylhydantoin had no enhancing activity, whereas the phenobarbital in structure and, like phenobarbital, alters enhancing effect of DDT was similar to that of phenobarbi- the metabolism of other drugs by the liver. Diphenylhydan- tal.
    [Show full text]
  • Barbiturates for the Treatment of Alcohol Withdrawal Syndrome: ☆ a Systematic Review of Clinical Trials
    Journal of Critical Care 32 (2016) 101–107 Contents lists available at ScienceDirect Journal of Critical Care journal homepage: www.jccjournal.org Barbiturates for the treatment of alcohol withdrawal syndrome: ☆ A systematic review of clinical trials Yoonsun Mo, MS, Pharm.D., BCPS, BCCCP a,b,⁎, Michael C. Thomas, Pharm.D., BCPS, FCCP a,1, George E. Karras Jr., MD, FCCM b,2 a Department of Pharmacy Practice, Western New England University College of Pharmacy, 1215 Wilbraham Road, Springfield, MA 01119 b Mercy Medical Center, 271 Carew Street, Springfield, MA 01104 article info abstract Keywords: Purpose: To perform a systematic review of the clinical trials concerning the use of barbiturates for the treatment Barbiturates of acute alcohol withdrawal syndrome (AWS). Phenobarbital Materials and Methods: A literature search of MEDLINE, EMBASE, and the Cochrane Library, together with a man- Benzodiazepines ual citation review was conducted. We selected English-language clinical trials (controlled and observational Alcohol withdrawal syndrome studies) evaluating the efficacy and safety of barbiturates compared with benzodiazepine (BZD) therapy for Delirium tremens Systematic review the treatment of AWS in the acute care setting. Data extracted from the included trials were duration of delirium, number of seizures, length of intensive care unit and hospital stay, cumulated doses of barbiturates and BZDs, and respiratory or cardiac complications. Results: Seven studies consisting of 4 prospective controlled and 3 retrospective trials were identified. Results from all the included studies suggest that barbiturates alone or in combination with BZDs are at least as effective as BZDs in the treatment of AWS. Furthermore, barbiturates appear to have acceptable tolerability and safety pro- files, which were similar to those of BZDs in patients with AWS.
    [Show full text]
  • Original Article Effects of Repeated High Dosage of Chloral Hydrate and Pentobarbital Sodium Anesthesia on Hepatocellular System in Rats
    Int J Clin Exp Med 2015;8(7):10568-10576 www.ijcem.com /ISSN:1940-5901/IJCEM0008402 Original Article Effects of repeated high dosage of chloral hydrate and pentobarbital sodium anesthesia on hepatocellular system in rats Jianhong Yu1*, Xuehui Sun2*, Guifeng Sang3 1Department of Anesthesiology, Yuhuangding Hospital, Yantai 264000, China; 2Department of Rheumatology, Yuhuangding Hospital, Yantai 264000, China; 3Operating Room, Yuhuangding Hospital, Yantai 264000, China. *Equal contributors. Received March 24, 2015; Accepted July 2, 2015; Epub July 15, 2015; Published July 30, 2015 Abstract: This study aims to investigate the possible effects of repeated high dosage of chloral hydrate and pen- tobarbital sodium anesthesia on hepatocellular system in rats. Thirty Sprague Dawley rats were randomly divided into 3 groups: control group (group A), chloral hydrate group (group B) and pentobarbital sodium group (group C). Antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione s transferase (GST) and catalase (CAT) activities and thiobarbituric acid-reactive substances (TBARS) level as well as serum biochemi- cal parameters alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (T-BIL) were determined. Liver histopathological examinations were performed at termination. Furthermore, Bax and Bcl-2 expression, and caspase-3 activity were also evaluated. The SOD, GSH-Px, GST and CAT activities significantly decreased but TBARS levels increased in group B and C compared with group A. Hepatic injury was evidenced by a significant increase in serum ALT, AST and ALP activities in group B and C, which also con- firmed by the histopathological alterations. Moreover, administration of chloral hydrate and pentobarbital sodium could induce certain hepatic apoptosis accompanied by the upregulated Bax expression, the downregulated Bcl-2 expression and Bcl-2/Bax ratio, and the increase of caspase-3 activity.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • Article on Relative Abuse Liability of Triazolam
    Neuroscience & giobehaviora[Reviews. Vol. 9, pp. 133-151. 19_5. e Ankho International Inc. Printed in the U.S.A 0149-7634/85 5300 ÷ 00 Relative Abuse Liability of Triazolam: Experimental Assessment in Animals and Humans ROLAND R. GRIFFITHS,** RICHARD J. LAMB,* NANCY A. ATOR,* JOHN D. ROACHE* AND JOSEPH V. BRADY** Departments of *Psychiatry and tNeuroscience. The Johns Hopkins University School of Medicine 720 Rutland Avenue, Baltimore, MD 21205 GRIFFITHS, R. R., R. J. LAMB, N. A. ATOR, J. D. ROACHE AND J. V. BRADY. Relative abuse liability oftriazolam: Experimental assessment in animals and humans. NEUROSCI BIOBEHAV REV 9(1) 133--151. 1985.--The abuse liability of a drug is a positive, interactive function of the reinforcing and adverse effects of the drug. The relative abuse liability of the hypnotic henzodiazepine, triazoiam, has been controversial. This paper reviews animal and human studies beating on its relative abuse liability, including data on pharmacological profile, reinforcing effects, liking, speed of onset, discrimina- tive stimulus effects, subjective effects, physiological dependence, rebound and early morning insomnia, drug produced anxiety, lethality in overdose, psychomotor impairment, interactions with ethanol anterogr_e amnesia, impaired aware- ness of drug effect, and other psychiatric and behavioral disturbances. It is concluded that the abuse liability of triazolam is less than that of the intermediate duration barbiturates such as pentobarbital. Although there are considerable data indicating similarities of triazolam to other benzodiazepines, there is also substantial speculation among clinical inves- til_tors and some limited data suggesting that the abuse liability of triazolam is greater than that of a variety of other benzodiazepines, and virtually no credible data or speculation that it is less.
    [Show full text]
  • Management of Drug and Alcohol Withdrawal
    The new england journal of medicine review article current concepts Management of Drug and Alcohol Withdrawal Thomas R. Kosten, M.D., and Patrick G. O’Connor, M.D., M.P.H. From the Departments of Psychiatry (T.R.K.) ach year in the united states, approximately 8.2 million persons and Medicine (P.G.O.), Yale University are dependent on alcohol and 3.5 million are dependent on illicit drugs, includ- School of Medicine, New Haven, Conn.; e 1 and Veterans Affairs Connecticut Health- ing stimulants (1 million) and heroin (750,000). In a sample from primary care care System, West Haven, Conn. (T.R.K.). practice, 15 percent of patients had either an “at-risk” pattern of alcohol use or an alco- Address reprint requests to Dr. Kosten at hol-related health problem, and 5 percent had a history of illicit-drug use.2 With rates of Veterans Affairs Connecticut Healthcare System, Psychiatry 151D, 950 Campbell substance use so high, all patients should be carefully screened with validated instru- Ave., Bldg. 35, West Haven, CT 06516, or ments such as the CAGE questionnaire for alcohol dependence, which consists of the at [email protected]. following questions: Can you cut down on your drinking? Are you annoyed when asked N Engl J Med 2003;348:1786-95. to stop drinking? Do you feel guilty about your drinking? Do you need an eye-opener Copyright © 2003 Massachusetts Medical Society. drink when you get up in the morning? Physicians should be prepared to treat patients who have withdrawal syndromes.3 A carefully taken history should include the time of last use for each substance involved, and toxicologic screening should be performed to identify any additional substances used.
    [Show full text]
  • Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, Mrna Levels, and Protein Expression Brittany T
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 8-2016 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Brittany T. Wright University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Neurosciences Commons Recommended Citation Wright, Brittany T. (http://orcid.org/0000-0002-1501-6596), "Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression" (2016). Theses and Dissertations (ETD). Paper 406. http://dx.doi.org/10.21007/ etd.cghs.2016.0408. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Neuroscience Research Advisor Scott A. Heldt, Ph.D. Committee Kristin M. Hamre, Ph.D. Michael P. McDonald, Ph.D. Kazuko Sakata, Ph.D. Jeffery D. Steketee, Ph.D. ORCID http://orcid.org/0000-0002-1501-6596 DOI 10.21007/etd.cghs.2016.0408 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/406 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Brittany T.
    [Show full text]
  • Associated Neuronal Injury
    BRIEF COMMUNICATION Phenobarbital and Midazolam (i.p.) at P6, and the next day SE was induced with subcutane- ous (s.c.) pilocarpine hydrochloride (320mg/kg) together with Increase Neonatal Seizure- scopolamine methyl chloride (1mg/kg, i.p.) to block the periph- eral effect of pilocarpine. All experiments were conducted with Associated Neuronal Injury the approval of and in accordance with the regulations of the Institutional Animal Care and Use Committee of West Los Angeles VA Medical Center, and in accordance with the U.S. Daniel, Torolira, BS,1 1 Public Health Service’s Policy on Humane Care and Use of Lucie, Suchomelova, PhD, Laboratory Animals. 1,2,3 Claude G., Wasterlain, MD, and In preliminary experiments, we found that high doses of 1,2 Jerome, Niquet, PhD midazolam (6mg/kg, but not 3mg/kg) and phenobarbital (25mg/kg, but not 10mg/kg) induce apoptosis in control Status epilepticus is common in neonates and infants, (no-seizure) pups. Ten minutes after the development of stage 3 and is associated with neuronal injury and adverse seizures, some pups were treated with midazolam (3mg/kg, i.p., developmental outcomes. c-Aminobutyric acidergic SE1Mz group, n 5 36) and others with phenobarbital (10mg/ (GABAergic) drugs, the standard treatment for neona- kg, i.p., SE1Ph group, n 5 26). Some pups (SE group, tal seizures, can have excitatory effects in the neonatal brain, which may worsen the seizures and their effects. n 5 30) were kept untreated as SE controls and only received Using a recently developed model of status epilepticus saline (i.p.), whereas other pups receiving only midazolam in postnatal day 7 rat pups that results in widespread (3mg/kg, i.p., Mz group, n 5 6) or phenobarbital (10mg/kg, neuronal injury, we found that the GABAA agonists i.p., Ph group, n 5 8) were kept as no-seizure controls for phenobarbital and midazolam significantly increased injury comparison.
    [Show full text]
  • Phenobarbital Compared to Benzodiazepines in Alcohol Withdrawal
    Drug and Alcohol Dependence 161 (2016) 258–264 Contents lists available at ScienceDirect Drug and Alcohol Dependence j ournal homepage: www.elsevier.com/locate/drugalcdep Full length article Phenobarbital compared to benzodiazepines in alcohol withdrawal treatment: A register-based cohort study of subsequent benzodiazepine use, alcohol recidivism and mortality a,∗ b c c Gro Askgaard , Jesper Hallas , Anders Fink-Jensen , Anna Camilla Molander , b b Kenneth Grønkjær Madsen , Anton Pottegård a Department of Hepatology, Copenhagen University Hospital, Rigshospitalet, Denmark b Clinical Pharmacology, Department of Public Health, University of Southern Denmark, DK-5000 Odense C, Denmark c Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen and Department of Neuroscience and Pharmacology, University of Copenhagen, DK-2100 Copenhagen, Denmark a r a t i c b s t l e i n f o r a c t Article history: Background: Long-acting benzodiazepines such as chlordiazepoxide are recommended as first-line treat- Received 16 December 2015 ment for alcohol withdrawal. These drugs are known for their abuse liability and might increase alcohol Received in revised form 28 January 2016 consumption among problem drinkers. Phenobarbital could be an alternative treatment option, possi- Accepted 5 February 2016 bly with the drawback of a more pronounced acute toxicity. We evaluated if phenobarbital compared Available online 18 February 2016 to chlordiazepoxide decreased the risk of subsequent use of benzodiazepines, alcohol recidivism and mortality. Keywords: Methods: The study was a register-based cohort study of patients admitted for alcohol withdrawal Alcohol withdrawal Benzodiazepines 1998–2013 and treated with either phenobarbital or chlordiazepoxide. Patients were followed for one Barbiturates year.
    [Show full text]
  • Effect of Acute Hypoxia Or Chronic Social Isolation on Brain Sensitivity and Barbiturate Metabolism
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1970 Effect of Acute Hypoxia or Chronic Social Isolation on Brain Sensitivity and Barbiturate Metabolism Irwin Paul Baumel University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Baumel, Irwin Paul, "Effect of Acute Hypoxia or Chronic Social Isolation on Brain Sensitivity and Barbiturate Metabolism" (1970). Open Access Dissertations. Paper 140. https://digitalcommons.uri.edu/oa_diss/140 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. EFFECT OF ACUTE HYPOXIA OR CHRONIC SOCIAL ISOLATION ON BRAIN SENSITIVITY AND BARBITURATE METABOLISM BY IRWIN PAUL BAUMEL A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACOLO GY AND TOXICOLOGY UNIVE RSITY OF RHODE ISLAND 1970 DOCTOR OF PHILOSOPHY THESIS OF IRWIN PAUL BAUMEL Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1970 i ABSTRACT Baumel, Irwin Paul, Ph.D., University of Rhode Island, July, 19705 Effect of Acute Hypoxia or Chronic Social Isolation on Brain Sensitivity and Barbiturate Metabolism. The mechanisms by which hypoxia or social isola­ tion interact with drug action were investigated by the use of several parameters including drug-induced narcosis, con- vulsions, change in body temperature and various biochem- ical parameters. Acute Hypoxia Hypobaric hypoxia (364 mm Hg, 10% 02) enhanced. the depressant effects of barbital, pentobarbital and chloral hydrate in mice and rats, Mice were far more sensitive than rats, barbital narcosis being affected to the greatest extent.
    [Show full text]
  • Relative Abuse Liability of GHB in Humans
    Neuropsychopharmacology (2006) 31, 2537–2551 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Relative Abuse Liability of GHB in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects of Supratherapeutic Doses of Triazolam, Pentobarbital, and GHB Lawrence P Carter1, Brian D Richards1, Miriam Z Mintzer1 and Roland R Griffiths*,1,2 1 2 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA Although preclinical studies suggest that GHB has low likelihood for abuse, case reports indicate that GHB is abused. This study evaluated the relative abuse liability of GHB in 14 volunteers with histories of drug abuse. Psychomotor, subjective, and cognitive effects of a broad range of GHB doses (2–18 g/70 kg), up to a dose that produced severe behavioral impairment in each participant, were compared to placebo and two abused sedative/hypnotic drugs, triazolam (0.5 and 1 mg/70 kg) and pentobarbital (200 and 400 mg/70 kg), under double-blind, double-dummy conditions at a residential research facility. In general, GHB produced effects similar to triazolam and pentobarbital, although GHB was not identified as a benzodiazepine or barbiturate by participants that correctly identified triazolam and pentobarbital as such. On most measures of likelihood of abuse (eg ratings of liking, reinforcing effects), effects of pentobarbital were significantly greater than those of triazolam, with GHB being intermediate. GHB produced significantly greater negative subjective effects, including nausea, than the other drugs. Memory impairment after GHB was less than that after triazolam and pentobarbital.
    [Show full text]